Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome
Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome
复制标题
DOI：
10.3390/nu10121971
复制
发表时间：
2018-12-01
期刊：
影响因子：
5.9
通讯作者：
Savastano, Silvia
中科院分区：
文献类型：
--
作者：
Barrea, Luigi;Annunziata, Giuseppe;Savastano, Silvia
肠道来源的代谢物三甲胺-N-氧化物（TMAO）与肥胖相关疾病之间存在机制联系，表明TMAO途径也可能与肥胖的发病机制有关。内脏肥胖指数 (VAI) 是脂肪功能障碍的性别特异性指标，脂肪肝指数 (FLI) 是非酒精性脂肪肝疾病 (NAFLD) 的预测因子，是代谢综合征 (MetS) 的早期预测因子。在这项横断面观察性研究中，我们调查了根据体重指数 (BMI) 分层的成年人的 TMAO 水平以及 TMAO 与 VAI 和 FLI 的关联。招募了 137 名成年受试者（59 名男性；21-56 岁）。使用 HPLC/MS 分析检测 TMAO 水平。胰岛素抵抗稳态模型评估 (HoMA-IR)、VAI 和 FLI 被纳入心脏代谢指数。 TMAO 水平随着 BMI 的增加而增加，并且在共同潜在协变量上与 VAI 和 FLI 独立呈正相关。预测 NAFLD-FLI 和 MetS 存在的 TMAO 循环水平的最敏感和具体截止值分别为 8.02 μM 和 8.74 μM。这些发现使我们能够假设 TMAO 作为脂肪功能障碍和 NAFLD-FLI 的早期生物标志物，在所有不存在明显 MetS 的临界条件下发挥作用，并表明 TMAO 的特定截止值可能有助于识别 NAFLD 高风险受试者。
There is a mechanistic link between the gut-derived metabolite trimethylamine-N-oxide (TMAO) and obesity-related diseases, suggesting that the TMAO pathway may also be linked to the pathogenesis of obesity. The Visceral Adiposity Index (VAI), a gender-specific indicator of adipose dysfunction, and the Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD), are early predictors of metabolic syndrome (MetS). In this cross-sectional observational study, we investigated TMAO levels in adults stratified according to Body Mass Index (BMI) and the association of TMAO with VAI and FLI. One hundred and thirty-seven adult subjects (59 males; 21-56 years) were enrolled. TMAO levels were detected using HPLC/MS analysis. Homeostatic Model Assessment of Insulin Resistance (HoMA-IR), VAI and FLI were included as cardio-metabolic indices. TMAO levels increased along with BMI and were positively associated with VAI and FLI, independently, on common potential covariates. The most sensitive and specific cut-offs for circulating levels of TMAO to predict the presence of NAFLD-FLI and MetS were 8.02 mu M and 8.74 mu M, respectively. These findings allow us to hypothesize a role of TMAO as an early biomarker of adipose dysfunction and NAFLD-FLI in all borderline conditions in which overt MetS is not present, and suggest that a specific cut-off of TMAO might help in identifying subjects at high risk of NAFLD.